Sphingolipid-derived pharmaceutical compositions

Details Sphingolipid-derived pharmaceutical compositions Sphingolipid-derived pharmaceutical compositions

2005-06-29

2009-12-08

Krass, Frederick (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S183000

Reexamination Certificate

active

07629385

ABSTRACT:
The present invention relates to specific sphingolipids/sphingolipid derivatives as pharmaceutical compositions as well as their use in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.

REFERENCES:
patent: 19841794 (2000-03-01), None
patent: 1 291 430 (2003-03-01), None
patent: 08 113535 (1996-05-01), None
patent: WO 94/10991 (1993-10-01), None
patent: WO 98/02153 (1998-01-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 01/22957 (2001-04-01), None
patent: WO 2004/006483 (2004-05-01), None
Rosenwald et. al., The Journal of Biological Chemistry (1993) 268:4577-4579.
McReynolds et. al., Bioorganic and Medicinal Chemistry (2002) 10:625-637.
“Inhibitor against nerve cell degeneration or death—comprises N-acyl-sphingosine or sphingo-myelinase, used for treating degenerative diseases or injuries e.g. trauma and Alzheimer's disease,” Database WPI, Derwent Publications Ltd., AN 1996/272724, 1996.
Anderson et al., “Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae,”Molecular Biology of the Cell, 7: 1825-1834, 1996.
Damm et al., “Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae,”The Journal of Cellular Biology, 168: 477-488, 2005.
Gidwani et al., “Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FcεRI,”Journal of Cell Science, 116: 3177-3187, 2003.
Hussey et al., “Synthesis of chimeric 7alpha-substituted estradiol derivatives linked to cholesterol and cholesterylamine,”Org. Lett., 4: 415-418, 2002.
Ito, “N-acylsphingosine and sphingomyelinase as inhibitors of neuron degeneration and death,” Chemicals Abstracts Service, Database accession No. 1996:464360, 1996.
Koskinen and Koskinen, “Sphingosine, an enigmatic lipid: a review of recent litature synthesis,”Synthesis, 1075-1091, 1998.
Koskinen and Koskinen, “Total synthesis of sphingosine and its analogs,”Methods of Enzymologys, 311:458-479, 1998.
Nguyen et al., “Practical synthetic route to functionalized rhodamine dyes,”Org. Lett., 5: 3245-3248, 2003.
Pelkmans et al., “Local Actin Polymerication and Dynamin Recruitment in SV40-Inuduced Internalization of Caveolae,”Science, 296: 535-539, 2002.
Pelkmans et al., “Caveolar endocytosis of simina virus 40 reveals a new two-step vesicular-transport pathway to the ER,”Nature Cell Biol., 3: 473-483, 2001.
Rosenwald and Pagano, “Inhibition of Glycoprotein Traffic through the Secretory Pathway by Ceramide,”The Journal of Biological Chemistry, 268: 4577-4579, 1993.
Sieczkarski and Whittaker, “Differential Requirements of Rab5 and Rab7 for Endocytosis of Influenza and Oether Enveloped Viruses,”Traffic, 4: 333-343.
Simons and Vaz, “Model Systems, lipid rafts, and cell membrances,”Annu. Rev. Biophys. Biomol. Struct., 33: 269-295, 2004.
Stang et al., “Major histocompatibility complex class I molecules mediate association of SV40 with caveolae,”Mol. Biol. Cell, 8: 47-57, 1997.
Wang et al., “Fluorescence-based evaluation of the partitioning of lipids and lipidated peptides into liquid-ordered lipid microdomains: a model for molecular partitioning into ‘lipid rafts’,”Biophys. J., 79: 919-933, 2000.
Wang et al., “Relationship between sterol/steroid structure and participation in ordered lipid domains (lipid rafts): implications for lipid raft structure and function,”Biochemistry, 43: 1010-1018, 2004.
European Search Report, mailed Oct. 17, 2007.
Rosenwald and Pagano, “Inhibition of glycoprotein traffic through the scretory pathway by ceramide,”J. Bio. Chem., 268:4577-4579, 1993.
European Search Report issued in European Application No. 08021735.9, mailed Aug. 6, 2009.

Affiliated with

Also associated with

Rating

Sphingolipid-derived pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sphingolipid-derived pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sphingolipid-derived pharmaceutical compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134545